Using controlled clinical trials to learn more about acute drug-induced liver injury

Hepatology

Volumn 48, Issue 5, 2008, Pages 1680-1689

  Watkins, Paul B ^a   Seligman, Paul J ^b   Pears, John S ^c   Avigan, Mark I ^b   Senior, John R ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; BROMFENAC; HEPARIN; ISONIAZID; MEVINOLIN; NEW DRUG; PLACEBO; TACRINE; TROGLITAZONE; DRUG;

ACUTE DISEASE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALZHEIMER DISEASE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL INDICATOR; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL; COMMON BILE DUCT STONE; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DATA COLLECTION METHOD; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RECHALLENGE; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED PRACTICE; HUMAN; IMMUNOLOGICAL TOLERANCE; JAUNDICE; LABORATORY TEST; LIVER INJURY; LIVER PROTECTION; LIVER TOXICITY; MEDICAL EXPERT; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL VALUE; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RELIABILITY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; VIRUS HEPATITIS; ARTICLE; BLOOD; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; DRUG INDUSTRY; HOSPITALIZATION; INJURY; LIVER; REPRODUCIBILITY; STANDARD;

ALANINE TRANSAMINASE; BIOLOGICAL MARKERS; CONTROLLED CLINICAL TRIALS AS TOPIC; DRUG INDUSTRY; HUMANS; LIVER; PHARMACEUTICAL PREPARATIONS; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX;

EID: 56149105113     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22633     Document Type: Conference Paper

References (71)

1. Temple R. Hepatotoxicity through the years: Impact on the FDA. Presented at the "Drug-Induced Liver Injury: A National and Global Problem" conference, Chantilly, VA, February 12-13, 2001. www.fda.gov/cder/livertox/meeting2001.htm#Drug-Induced. Accessed September 2008.
2. Ostapowicz G, Fontana R, Schiødt F, Larson A, Davern T, Han SH, et al.. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137:947-954.
3. FDA. Draft Guidance for Industry. Drug-Induced Liver Injury: Premarketing Clinical Evaluation. www.fda.gov/cder/guidance/7507dft.htm. Accessed September 2008.
4. FDA/CDER-PhRMA-AASLD. Program: Detecting and Investigating Drug-Induced Liver Injury During Clinical Trials. www.fda.gov/cder/livertox/ presentations2008/Program_08.pdf. Accessed September 2008.
5. FDA Center for Drug Evaluation and Research. AASLD-FDA-NIHPhRMA Hepatotoxicity Special Interest Group Meeting 2008 presentations. www.fda.gov/cder/livertox/presentations2008.htm. Accessed September 2008.
6. Karmen A. A note on the spectrometric assay of glutamic oxalacetic transaminase in human blood serum. J Clin Invest 1955;34:131-133.
7. Lindblom P, Rafter I, Cooley C, Andersson U, Hedberg JJ, Berg AL, et al. Isoforms of alanine aminotransferases in human tissues and serum-differential tissue expression using novel antibodies. Arch Biochem Biophys 2007;466:66-77.
8. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994;271:992-998.
9. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998;338:916-917.
10. Graham DJ, Green L, Senior JR, Nourjah P. Troglitazone-induced liver failure: A case study. Am J Med 2003;114:299-306.
11. Davidson CS, Leevy CM, Chamberlayne EC. Guidelines for detection of hepatotoxicity due to drugs and chemicals. (Fogarty Conference, 1978) National Institutes of Health Publication 79-313. Washington, DC: US Government Printing Office; 1979:114.
12. Mitchell JR, Long MW, Thorgeirsson UP, Jollow DJ. Acetylation rates and monthly liver function tests during one year of isoniazid preventative therapy. Chest 1975;68:181-190.
13. Shayiq RM, Roberts DW, Rothstein K, Snawder JE, Benson W, Ma X, et al. Repeat exposure to incremental doses of acetaminophen provides protection against acetaminophen-induced lethality in mice: An explanation for high acetaminophen dosage in humans without hepatic injury. HEPATOLOGY 1999;29:451-463.
14. Aleksunes LM, Slitt AM, Cherrington NJ, Thibodeau MS, Klaassen CD, Manatou JE. Differential expression of mouse hepatic transporter genes in response to acetaminophen and carbon tetrachloride. Toxicol Sci 2005;83: 44-52.
15. Masson MJ, Peterson RA, Chung CJ, Graf ML, Carpenter LD, Ambroso JL, et al. Lymphocyte loss and immunosuppression following acetaminophen- induced hepatotoxicity in mice as a potential mechanism of tolerance. Chem Res Toxicol 2007;20:20-26.
16. Senior JR. Liver adaptation to xenobiotic injury. www.fda.gov/cder/ livertox/presentations2006/Senior.pdf. Accessed September 2008.
17. Watkins PB. Insight into hepatotoxicity: The troglitazone experience. HEPATOLOGY 2005;41:229-230.
18. Chalasani N. Clinical meaning of elevated aminotransferase activity. www.fda.gov/cder/livertox/presentations2008/A-Chalasani2.pdf. Accessed September 2008.
19. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1-10.
20. Cai J. Question raised in discussion of Session IA and IB, March 26, 2008. www.fda.gov/cder/livertox/presentations2008/12-d1b.pdf. Accessed September 2008.
21. Senior JR. Lessons from isoniazid: Would it be approved today? (slide 12) www.fda.gov/cder/livertox/presentations2008/C-Senior2.pdf. Accessed September 2008.
22. Zimmerman HJ. The spectrum of hepatotoxicity. (Kober Lecture). Perspect Biol Med 1968;12:135-161.
23. Zimmerman HJ. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. New York, NY: Appleton-Century-Crofts; 1978: 351-357.
24. Zimmerman HJ. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. 2nd ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 1999:428-430.
25. Center for Drug Evaluation and Research Staff College Course. Drugs and the liver: What they do to each other. April 1999. www.fda.gov/cder/ livertox/courses.pdf. Accessed September 2008.
26. Reuben A. Hy's law explained. www.fda.gov/cder/livertox/ presentations2008/E-Reuben2.pdf. Accessed Septmber 2008.
27. Björnsson E, Olsson R. Outcome and prognostic markers in severe druginduced liver disease. HEPATOLOGY 2005;42:481-489.
28. Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Pachkoria K, Garcia-Ruiz E, et al. Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005;129:512-521.
29. Rockey DC. Was it the drug, or a disease? How to determine it. www.fda.gov/cder/livertox/presentations2008/F-Rockey2.pdf. Accessed September 2008.
30. Tipping RW. Liver test elevations in patients on placebo. www.fda.gov/ cder/livertox/presentations2008/B-Tipping2.pdf. Accessed September 2008.
31. Watkins PB. DILIN Consensus Opinions on Concept Document. www.fda.gov/ cder/livertox/presentations2007/Watkins.pdf. Accessed September 2008.
32. Goldkind SF. Ethical perspectives on drug-induced liver injury: premarketing clinical evaluation. www.fda.gov/cder/livertox/ presentations2008/K-Goldkind2.pdf. Accessed September 2008.
33. Uetrecht J. Immune-allergic sensitization to a xenobiotic. www.fda.gov/ cder/livertox/presentations2008/G-Uetrecht2.pdf. Accessed September 2008.
34. Seeff L. How much do we need to know about rechallenge? www.fda.gov/ cder/livertox/presentations2008/H-Seeff.pdf. Accessed September 2008.
35. Nolan CM, Goldberg SV, Ruskin SE. Hepatotoxicity associated with isoniazid preventative therapy: A 7-year survey from a public health tuberculosis clinic. JAMA 1999;281:1014-1018.
36. Papay J, Hunt CM. Positive rechallenge following drug-induced liver injury: A review of 88 cases. www.fda.gov/cder/livertox/ presentations2008/J-PapayHunt2.pdf. Accessed September 2008.
37. Barth J. Industry perspectives. www.fda.gov/cder/livertox/ presentations2008/L-Barth2.pdf. Accessed September 2008.
38. Bartholomaeus A. International regulatory perspective on guidelines for drug development and testing. www.fda.gov/cder/livertox/ presentations2008/M-Bartholomaeus2.pdf. Accessed September 2008.
39. Temple RJ. Should patients with stable liver disease be included? www.fda.gov/cder/livertox/presentations2008/N-Temple2.pdf. Accessed September 2008.
40. Lee WM. Patients with pre-existing liver disease should be included in clinical trials prior to approval. www.fda.gov/cder/livertox/ presentations2008/P-Lee2.pdf. Accessed September 2008.
41. Regev A. Patients with underlying liver disease: Why should we continue to exclude them? www.fda.gov/cder/livertox/presentations2008/ Q-Regev2.pdf. Accessed September 2008.
42. Ito H, Yoshioka K, Ukai K, Watanabe K, Yano M, Ishigami M, et al. The fluctuations of viral load and serum alanine aminotransferase levels in chronic hepatitis C. Hepatol Res 2004;30:11-17.
43. Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol 2007;17:863-869.
44. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231.
45. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98: 960-967.
46. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 199.9;341:556-562.
47. Dasarathy A, McCullough AJ. Alcoholic liver disease. In: SchiffER, Sorrell MF, Maddrey WC, eds. Schiff's Diseases of the Liver. Philadelphia, PA: Lippincott Williams & Wilkins; 2007:881-922.
48. McQuillan GM, Coleman PJ, Kruszon-Moran D, Moyer LA, Lambert SB, Margolis HS. Prevalence of hepatitis B virus infection in the United States: The National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999;89:14-18.
49. Wong WM, Wu PC, Yuen MF, Cheng CC, Yew WW, Wong PC, et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. HEPATOLOGY 2000;31:201-206.
50. Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D, Albanese AP, et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998;157(6 Pt 1):1871-1876.
51. Bonacini M. Liver injury during highly active antiretroviral therapy: the effect of hepatitis C co-infection. Clin Infect Dis 2004;38(Suppl 2):S104-S108.
52. Kramer JR, Giordano TP, Souchek. J, El-Serag HB. Hepatitis C co-infection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era. J Hepatol 2005;42:309-314.
53. Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkins lymphoma: A randomized trial. HEPATOLOGY 2008;47:844-853.
54. Garcia-Buey L, Garcia-Monzon C, Rodriguez S, Borque MJ, García-Sánchez A, Iglesias R, et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology 1995;108:1770-1777.
55. Bruno S, Maisonneuve P, Castellana P, Rotmensz N, Rossi S, Maggioni M, et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ 2005;330:932.
56. Rosenberg P, Urwitz H, Johannesson A, Ros AM, Lindholm J, Kinnman N, et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol 2007;46:995-998.
57. Avigan M. What kind of a biomarker do we need? www.fda.gov/cder/livertox/ presentations2008/R-Avigan2.pdf. Accessed September 2008.
58. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005;4:489-499.
59. Lee WM. Drug-Induced hepatotoxicity. N Eno J Med 2003;349:474-485.
60. Gunawan BK, Kaplowitz N. Mechanisms of drug-induced liver disease. Clin Liver Dis 2007; 11:459-475.
61. Russo M, Watkins PB. Genetic basis for susceptibility to Drug Induced Liver Injury. In: Drug-Induced Liver Disease. Kaplowitz N, Deleve L, eds. New York, NY: Informa, Health Care, USA, Inc.; 2007:105-125.
62. Holden A. Detecting and investigating drug-induced adverse events: The international Serious Adverse Event Consortium's experience. www.fda.gov/ cder/livertox/presentations2008/T-Holden2.pdf. Accessed September 2008.
63. Roses AD, Saunders AM, Huang Y, Strum J, Weisgraber KH, Mahley RW. Complex disease-associated pharmacogenetics: Drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease). Pharmacogenomics J 2007;7:10-28.
64. Hinds DA, Stuve LL, Nilsen GB, Halperin E, Eskin E, Ballinger DG, et al. Whole-genome patterns of common DNA variation in three human populations. Science 2005;307:1052-1053.
65. Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bengtsson OF, Andersson TB, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 2008;8:186-195.
66. Bloom JC. Finding biomarkers to predict and manage serious drug-induced liver injury; where to look www.fda.gov/cder/livercox/presentations2008/ S-BIoom2.pdf. Accessed September 2008.
67. Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, et al for the DILIN study group. Rationale, Design and Conduct of the Drug Induced Liver Injury Network (DILIN) Prospective study. Drug Saf. 2009. In press.
68. Freston JW. Looking for hepatotoxicity, working up patients, and assessing causality. www.fda.gov/cder/livertox/Presentations/im7130/ sld003.htm. Accessed September 2008.
69. Gelperin K, Guo T. A tool to help you decide (detect potentially serious liver injury). www.fda.gov/cder/livertox/presentations2008/ D-GelperinGuo2.pdf. Accessed September 2008.
70. Fontana R, Day C, Andrade R, Serrano J, Seeff LB. Drug-induced liver injury: Standardization of nomenclature and causality assessment. NIH workshop. www3.niddk.nih.gov/fund/other/diliworkshop2008. Accessed September 2008.
71. Kamath PS. The need for better clinical trials. HEPATOLOGY 2008;48:1-3.